前列腺癌原发治疗后复发患者的风险分层:一项系统综述
该研究依据PRISMA指南系统检索了2000年1月1日至2023年10月16日的前瞻性研究,共纳入37项研究(总n=10,632),其中前列腺切除术后25项(n=9,010)、放疗后12项(n=1,622)。综述识别了与不良肿瘤学结局相关的预后因素,并给出了风险分层的推荐与证据等级,可作为基于预后个体化挽救治疗的基准。
要点
- 前列腺切除术后复发的不良预后因素包括更高的病理T分期和分级分组、手术切缘阴性、更短PSADT、挽救治疗前更高PSA、更短至复发时间、22基因肿瘤RNA特征及分子影像上的复发位置。
- 放疗后复发的不良预后因素包括更短的至复发时间和更短PSADT或更高PSA速度。
- 分级分组、T分期和既往短期激素治疗(4-6个月)与不良结局未见明确关联,但样本量和随访一般有限。
核心结论
- 本工作突出了对前列腺癌复发患者进行风险分层的推荐和证据等级,可作为基于预后个体化挽救治疗的基准。
研究设计与样本
- 按照系统综述和Meta分析首选报告条目(PRISMA)指南,对EMBASE、MEDLINE和ClinicalTrials.gov(2000年1月1日至2023年10月16日)的前瞻性研究进行系统综述(CRD42023466330)。
- 共纳入37项研究(总n=10,632),其中前列腺切除术后25项(总n=9,010),放疗后12项(总n=1,622)。
主要发现
- 前列腺切除术后复发,与不良结局相关的因素包括更高的病理T分期和分级分组、手术切缘阴性、更短的前列腺特异性抗原倍增时间(PSADT)、挽救治疗前更高的前列腺特异性抗原(PSA)、更短的至复发时间、22基因肿瘤RNA特征以及分子影像上的复发位置。
- 放疗后复发,与不良结局相关的因素包括更短的至复发时间,以及更短的PSADT或更高的PSA速度。
- 分级分组、T分期和既往短期激素治疗(4-6个月)与不良结局未见明确关联,尽管与前列腺切除术后数据相比样本量和随访一般有限。
局限性
- 放疗后复发相关分析的样本量和随访一般有限,与前列腺切除术后数据相比。
- 分级分组、T分期和既往短期激素治疗(4-6个月)与不良结局未见明确关联,但样本量和随访一般有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes. METHODS: We performed a systematic review of prospective studies in EMBASE, MEDLINE, and ClinicalTrials.gov (from January 1, 2000 to October 16, 2023) according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines (CRD42023466330). We reviewed the factors associated with oncologic outcomes among patients with BCR after primary definitive treatment. KEY FINDINGS AND LIMITATIONS: A total of 37 studies were included (total n = 10 632), 25 after prostatectomy (total n = 9010) and 12 after radiotherapy (total n = 1622). Following recurrence after prostatectomy, factors associated with adverse outcomes include higher pathologic T stage and grade group, negative surgical margins, shorter prostate-specific antigen doubling time (PSADT), higher prostate-specific antigen (PSA) prior to salvage treatment, shorter time to recurrence, the 22-gene tumor RNA signature, and recurrence location on molecular imaging. After recurrence following radiotherapy, factors associated with adverse outcomes include a shorter time to recurrence, and shorter PSADT or higher PSA velocity. Grade group, T stage, and prior short-term hormone therapy (4-6 mo) were not clearly associated with adverse outcomes, although sample size and follow-up were generally limited compared with postprostatectomy data. CONCLUSIONS AND CLINICAL IMPLICATIONS: This work highlights the recommendations and level of evidence for risk stratifying patients with PCa recurrence, and can be used as a benchmark for personalizing salvage treatment based on prognostics.
引用
- Weiner AB, Kakani P, Armstrong AJ, et al. Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review. Eur Urol. 2024. PMID: 38782697. doi:10.1016/j.eururo.2024.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。